BASEL, Switzerland, June 3 /PRNewswire/ --
- Not for US Media
- New Ilaris Data in The New England Journal of Medicine Show Rapid Sustained Efficacy in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)(1)
- CAPS is a Debilitating Genetic Disorder With Potentially Fatal Complications and Limited Treatments Available(1),(2),(3)
- Ilaris Selectively Blocks Interleukin-1beta (IL-1beta), a Key Driver in Inflammation and Tissue Destruction - Therapy Being Investigated for Other Inflammatory Diseases(1),(3),(4)
- Regulatory Submissions Completed in Major Countries With Priority Review Granted in US, Switzerland and Australia